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Few data are in literature about the pharmacological treatment of conversion disorder and there are not any studies about the use
of Valproate extended release (ER) in treating conversion disorder. In this article, we are reporting a case of an Italian woman with
a diagnosis of conversion disorder treated eﬀectively and quickly by Valproate ER.
1.Introduction
The presence of neurological signs, as deﬁcits of sensitive
or motor activity, without any organic lesions, is actually
diagnosed as conversion disorder (DSM IV-TR) [1]. The
term conversion introduced by Sigmund Freud [2]a n du s e d
as a defence mechanism of the Ego, substituted the diagnosis
hysterical neurosis in DSM III (1980) [3].
Although the term hysteria comes from a Greek word,
meaning uterus, the ancient concept of hysteria was diﬀerent
from the current one [4]. Ancient Greek described a
syndrome characterized by numerous symptoms as stiﬂing,
aphonia, heart palpitation and other somatic symptoms,
but the hypothesis of unspeciﬁed behavioural disturbances,
caused by a displacement of the womb or by a “wandering
uterus” were not reported in ancient Egyptian nor in Greek
texts [5]. Hippocrates described the role of the womb in
the hysterike pnix, traduced as stiﬂing, but the Hippocratic
concept of hysteria was not linked to behavioural alterations
[6].
During the Middle Ages the magic and superstitious
vision was predominant in medicine and the “psychopathol-
ogy” of women with mental disorders, considered as witches,
was described in the Malleus Maleﬁcarum [7] (The Hammer
of Witches, 1486), a textbook that reported “every type
of neurosis or psychosis which we ﬁnd today in our daily
psychiatric work” [8].
After the superstitions linked to hysteria were gradually
abandoned and in Modern Age, Charles le Pois, for the ﬁrst
time, and others as Thomas Willis and Thomas Sydhenam
considered hysteria to have a cerebral cause and later Russell
Reynolds thought that some forms of paralysis could be
caused by an idea [9].
The association between a psychic disorder and the
somaticmanifestationswasconﬁrmedbyJeanMarieCharcot
who considered hysteria as a psychic disease “par excel-
lence” [10]. During his lec ¸ons du mardi (Tuesday lessons),
Charcot attracted many world physicians at Salpˆ etriere, to
show the phenomenology of grande hysterie with the body
characteristic phenomenology as the arc en cercle (extreme
opisthotonus), the grandes movements and the attitudes
passionelles (hallucinatory phase) [11]. Then in Freudian
theory, hysteria was seen as a consequence of a conﬂict
between unacceptable impulses, desires, thoughts and moral
instances [12]. The libido linked to repressed memories of
traumatic experiences or repressed sexual fantasies could be
converted into somatic symptoms [12].
Despite the fact that the libido hypothesis, as cause
of hysteria, has been rejected by authors who dispute the
psychoanalytic interpretation of psychiatric disease [13–
15], the hypothesis of an intrapsychic conﬂict could be
considered as ”an useful organizing concept” [16]a n da
combined neuroscientiﬁc-psychoanalytic approach could be
useful to investigate the neurophysiopathology of mental
disorders [17, 18] as well as the hysteria, however “there is
no generally accepted explanation for how a psychological
stress can change into (often highly selective) symptoms”
[19].2 Case Reports in Medicine
Actually functional neuroimaging researches have evi-
denced some cortical dysfunctions as a reduced activity in
motor, sensitive and visual cortical areas during hysterical
paralysis,hystericalanaesthesiaandhystericalblindness[20].
Hysteria remains the “bete noir” of medicine, the diag-
nosis is often uncertain and of exclusion without a speciﬁc
pharmacologic therapy.
In this article we describe a case of a woman with conver-
sion disorder treated with a pharmacological approach.
2.Case
A 34 years old woman was taken to the emergency room for
a loss of consciousness and an absence of stimulus-response
(attaques de sommeil [21]). No evidence of objective basis
were found after instrumental exams and specialistic con-
sults; this clinical condition continued for 48 hours.
When the woman became conscious, she said not to
remember anything about the event. She was discharged
from the emergency room and she was admitted in our
operative unit of psychiatry. She reported that for several
months she has been experiencing a loss of self control
(e.g. she cooked or remade the bed “without awareness”);
these episodes of “loss of awareness” lasted few minutes
(absences [21]). She also experienced dysperception as
dysmegalopsiaanderitropsia.Onapsychicexamsheshowed
no psychopathological signs, except a mild depressive status,
a lack of concern and feeling and an indiﬀerence about
her condition (belle indiﬀerence [21]). During the hospital-
ization she showed aphonia and astasia-abasia. Laboratory
test, CT, NMR, EEG were normal. On psychological test,
MMPI evidenced the presence of the so called “Conversion
V”, a condition in which depression has lower score than
hypochondrias and hysteria [21].
According to DSM-IV-TR [1] the diagnosis was conver-
sion disorder, non epileptic seizures subtype
She was treated with Citalopram at 20mg/die, that
induced an improvement in depressive symptoms and a
slight improvement in conversion symptoms. After 10 days
she was discharged.
Two weeks later she was seen again for a control visit,
while she was talking about the recrudescence of symptoms,
she suddenly was unable to speak, to stand up and to walk.
This symptomatology was acutely treated with Lorazepam
2.5mgperosanditremittedafter2hours.Thetreatmentwas
modiﬁed: Citalopram 20mg/die was suspended, and after a
written informed consent, Valproate extended release (ER)
300mg/die was added. After the addition of Valproate ER
the conversion symptoms rapidly and signiﬁcantly improved
a n da f t e ro n ey e a ro ff o l l o wu ps h ed i dn o th a v ea n y
symptoms, she didn’t lose consciousness and she did not
show aphonia or astasia-abasia.
3. Discussion
The absence of objective basis of the symptomatology
excludes the presence of an organic disease. The presence
of neuropsychiatric signs, as astasia-abasia, aphonia, dys-
perception and crepuscular state, without organic lesion
and electric abnormalities of brain to EEG, suggests the
diagnosis of a conversion disorder. The presence of psycho-
logical diﬃculties (conﬂicts with her husband), associated
to“Conversion V” on MMPI [22] conﬁrms the diagnosis. No
data can be found in literature about the use of Valproate
in conversion disorder. A Previous research reported the use
of lithium in conversion symptoms [23]. The mechanisms
of action of lithium and Valproate are similar. Both drugs
are inhibitors of voltage -dependent sodium and calcium
channels, of glutamate neurotransmission and of second
messengers (protein kinase C, inositol triphosphate and
diacylglycerol), while both drugs potentiate GABA neuro-
transmission [24]. The interpretation of action of Valproate
on conversion disorder is unclear. Stonnigton and coll. [25]
reported the utility of the assumption of antiepileptic drugs
in conversion patients with no epileptic seizures associated
with epilepsy, but in our case the presence of epilepsy was
excluded.
Despite some data in literature evidenced that GABAer-
gic anticonvulsant could induce pseudoseizures [26, 27], the
use of Valproate ER in no epileptic subjects is well tolerated
and it is not associated to a high incidence of side eﬀects as
pseudo epileptic seizures [28–32].
This article shows that the addition of Valproate ER in
therapy determined a remission of conversion symptoms.
After Valproate assumption the patient didn’t have episodes
of alteration of consciousness and did not show aphonia,
abasia-astasia.
We argue that the use of Valproate ER could accelerate
and maintain the remission of hysterical symptomatology.
Further researches on a larger sample need to investigate
on the eﬃcacy of Valproate ER in treating patients with
conversion disorder, and to verify also if the use of Valproate
ER could facilitate a more rapid resolution of symptoms.
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